The US Food and Drug Administration (FDA) has cleared the expanded use of the Vidas Brahms procalcitonin (PCT) test to help clinicians determine whether antibiotic treatment should be initiated or ...
FDA Logo High levels of PCT suggest a patient has a bacterial infection. The U.S. Food and Drug Administration (FDA) has expanded the use of the Vidas Brahms PCT Assay (bioMérieux) to help clinicians ...
Please provide your email address to receive an email when new articles are posted on . The FDA recently approved the expanded use of the Vidas Brahms PCT Assay, which guides antibiotic treatment ...
SILVER SPRING, Md., Feb. 23, 2017 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today cleared the expanded use of the Vidas Brahms PCT Assay to help health care providers determine ...
We have moved Diagnostics guidance 18 to become HealthTech guidance 386. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, ...
INDIANAPOLIS, March 23, 2016 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has submitted the Elecsys BRAHMS PCT (Procalcitonin) assay for Premarket Notification (510k) to the U.S ...
NICE has assessed the procalcitonin tests (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) to help ...
Imagine going to the hospital for a relatively minor condition like kidney stones or appendicitis and coming home without your arms or legs. This dramatic scenario is not only possible, but is ...
July 1 (Reuters) - Biomerieux SA : * Biomerieux receives FDA clearance for expanded use of VIDAS B.R.A.H.M.S PCT test for managing sepsis patients with elevated risk of mortality Source text for Eikon ...
Procalcitonin test demand from the emergency department is growing, necessitating the implementation of strategies to address overuse. Successful interventions must be based on information technology.
S Krüger and T Welte have received funds for speaking at symposia organized on behalf of Brahms AG. The authors have no other relevant affiliations or financial involvement with any organization or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results